Podcast PX Pulse

What Matters Right Now for Rolling Out the Ring and Injectable PrEP?

March 29, 2022

The HIV field has two new approved prevention options waiting in the wings, the dapivirine vaginal ring and injectable cabotegravir as PrEP. Until now, daily oral PrEP, first approved in 2012, has been the only drug-based strategy for HIV prevention.

So here we are: research has shown safety and efficacy for both the ring and injectable cabotegravir. Now it’s time to take the next steps to deliver these options and translate advances in science into real impact on the epidemic.

At AVAC, we’ve been calling for coordinated planning to introduce and rollout new products, while expanding access to existing options. These efforts must learn from the mistakes of the past, especially lessons from rolling out oral PrEP.

In this episode of PxPulseLinda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation and Lillian Mworeko from the International Community of Women Living with HIV East Africa (ICWEA) join host Jeanne Baron and AVAC’s Executive Director Mitchell Warren to discuss innovative models for scale-up and delivery. Taking the right steps now could mean HIV prevention options fulfill their life-saving, epidemic-ending potential, and to do so requires working faster and more efficiently than ever before.

We dive into what lessons the field has learned, what’s still off-track, and the steps advocates, policy makers, drug makers and funders should each take right now to turn efficacious options into effective choices.


Dapivirine Vaginal Ring
Ring and CAB

Subscribe to this Podcast

Adolescent Girls and Young Women
Cisgender Women
Advocating for Health Equity
Tracking and Translating the Field